PDZ结合激酶/T淋巴细胞因子激活的杀伤细胞源性蛋白激酶的作用机制及其在肿瘤治疗中的潜在价值

doi:10.3969/j.issn.1004-583X.2023.08.016

摘要/Abstract

摘要：

T淋巴细胞因子激活的杀伤细胞源性蛋白激酶(T-lymphokine-activated killer cell-originated protein kinase,TOPK)也被称为PDZ结合激酶(PDZ-binding kinase,PBK)。PBK/TOPK在有丝分裂进程中起至关重要的作用。PBK/TOPK被证实与恶性肿瘤的增殖、转移、侵袭及临床预后有关,因此,PBK/TOPK成为了肿瘤治疗一个具有吸引力的靶点。本文综述PBK/TOPK通过不同作用机制参与肿瘤的发生和发展,以进一步证实PBK/TOPK有望成为肿瘤治疗的靶点。

关键词: PDZ结合激酶/T淋巴细胞因子激活的杀伤细胞源性蛋白激酶, 肿瘤治疗方案, 作用机制

中图分类号:

R345.57

武锐锋, 刘宇宏. PDZ结合激酶/T淋巴细胞因子激活的杀伤细胞源性蛋白激酶的作用机制及其在肿瘤治疗中的潜在价值[J]. 临床荟萃, 2023, 38(8): 763-768.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2023.08.016

https://huicui.hebmu.edu.cn/CN/Y2023/V38/I8/763

图/表 2

参考文献 53

[1]	Li S, Zhu F, Zykova T, et al. T-LAK cell-originated protein kinase (TOPK) phosphorylation of MKP1 protein prevents solar ultraviolet light-induced inflammation through inhibition of the p38 protein signaling pathway[J]. J Biol Chem, 2011, 286(34):29601-29609. doi: 10.1074/jbc.M111.225813 pmid: 21715333
[2]	Nandi A, Tidwell M, Karp J, et al. Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells[J]. Blood Cells Mol Dis, 2004, 32(1):240-245. doi: 10.1016/j.bcmd.2003.10.004 URL
[3]	Simons-Evelyn M, Bailey-Dell K, Toretsky JA, et al. PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells[J]. Blood Cells Mol Dis, 2001, 27(5):825-829. doi: 10.1006/bcmd.2001.0452 URL
[4]	Zykova TA, Zhu F, Vakorina TI, et al. T-LAK cell-originated protein kinase (TOPK) phosphorylation of Prx1 at Ser-32 prevents UVB-induced apoptosis in RPMI7951 melanoma cells through the regulation of Prx1 peroxidase activity[J]. J Biol Chem, 2010, 285(38):29138-29146. doi: 10.1074/jbc.M110.135905 pmid: 20647304
[5]	Abe Y, Takeuchi T, Kagawa-Miki L, et al. A mitotic kinase TOPK enhances Cdk1/cyclin B1-dependent phosphorylation of PRC1 and promotes cytokinesis[J]. J Mol Biol, 2007, 370(2):231-245. doi: 10.1016/j.jmb.2007.04.067 pmid: 17512944
[6]	Dougherty JD, Garcia AD, Nakano I, et al. PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase[J]. J Neurosci, 2005, 25(46):10773-10785. doi: 10.1523/JNEUROSCI.3207-05.2005 pmid: 16291951
[7]	Han Z, Li L, Huang Y, et al. PBK/TOPK: a therapeutic target worthy of attention[J]. Cells, 2021, 10(2):371. doi: 10.3390/cells10020371 URL
[8]	Gaudet S, Branton D, Lue RA. Characterization of PDZ-binding kinase, a mitotic kinase[J]. Proc Natl Acad Sci USA, 2000, 97(10):5167-5172. doi: 10.1073/pnas.090102397 pmid: 10779557
[9]	Fujibuchi T, Abe Y, Takeuchi T, et al. Expression and phosphorylation of TOPK during spermatogenesis[J]. Dev Growth Differ, 2005, 47(9):637-644. doi: 10.1111/j.1440-169X.2005.00834.x pmid: 16316408
[10]	Park JH, Nishidate T, Nakamura Y, et al. Critical roles of T-LAK cell-originated protein kinase in cytokinesis[J]. Cancer Sci, 2010, 101(2):403-411. doi: 10.1111/cas.2010.101.issue-2 URL
[11]	Rizkallah R, Batsomboon P, Dudley GB, et al. Identification of the oncogenic kinase TOPK/PBK as a master mitotic regulator of C2H2 zinc finger proteins[J]. Oncotarget, 2015, 6(3):1446-1461. pmid: 25575812
[12]	Shinde SR, Gangula NR, Kavela S, et al. TOPK and PTEN participate in CHFR mediated mitotic checkpoint[J]. Cell Signal, 2013, 25(12):2511-2517. doi: 10.1016/j.cellsig.2013.08.013 pmid: 24012691
[13]	Ayllon V, O'Connor R. PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response[J]. Oncogene, 2007, 26(24):3451-3461. doi: 10.1038/sj.onc.1210142 pmid: 17160018
[14]	Park JH, Jeong YJ, Won HK, et al. Activation of TOPK by lipopolysaccharide promotes induction of inducible nitric oxide synthase through NF-kappaB activity in leukemia cells[J]. Cell Signal, 2014, 26(5):849-856. doi: 10.1016/j.cellsig.2014.01.004 URL
[15]	Lu H, Xiao J, Ke C, et al. TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ[J]. Cell Death Dis, 2019, 10(8):583. doi: 10.1038/s41419-019-1805-9 pmid: 31378785
[16]	Ma H, Li Y, Wang X, et al. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma[J]. Cell Death Dis, 2019, 10(3):166. doi: 10.1038/s41419-019-1415-6 pmid: 30778048
[17]	Chai Y, Xue H, Wu Y, et al. MicroRNA-216b-3p inhibits lung adenocarcinoma cell growth via regulating PDZ binding kinase/T-LAK-cell-originated protein kinase[J]. Exp Ther Med, 2018, 15(6):4822-4828. doi: 10.3892/etm.2018.6020 pmid: 29805502
[18]	Shih MC, Chen JY, Wu YC, et al. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer[J]. Oncogene, 2012, 31(19):2389-2400. doi: 10.1038/onc.2011.419 pmid: 21996732
[19]	Li Y, Yang Z, Li W, et al. TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun[J]. Oncotarget, 2016, 7(6):6748-6764. doi: 10.18632/oncotarget.6826 pmid: 26745678
[20]	Jiang Y, Zhang J, Zhao J, et al. TOPK promotes metastasis of esophageal squamous cell carcinoma by activating the Src/GSK3beta/STAT3 signaling pathway via gamma-catenin[J]. BMC Cancer, 2019, 19(1):1264. doi: 10.1186/s12885-019-6453-z
[21]	Ohashi T, Komatsu S, Ichikawa D, et al. Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma[J]. Br J Cancer, 2017, 116(2):218-226. doi: 10.1038/bjc.2016.394
[22]	Yang YF, Pan YH, Cao Y, et al. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of beta-Catenin signaling in hepatocellular carcinoma[J]. Oncotarget, 2017, 8(29):47195-47205. doi: 10.18632/oncotarget.v8i29 URL
[23]	Zhu F, Zykova TA, Kang BS, et al. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells[J]. Gastroenterology, 2007, 133(1):219-231. doi: 10.1053/j.gastro.2007.04.048 pmid: 17631144
[24]	Xiao J, Duan Q, Wang Z, et al. Phosphorylation of TOPK at Y74, Y272 by Src increases the stability of TOPK and promotes tumorigenesis of colon[J]. Oncotarget, 2016, 7(17):24483-24494. doi: 10.18632/oncotarget.8231 pmid: 27016416
[25]	Zykova TA, Zhu F, Wang L, et al. The T-LAK cell-originated protein kinase signal pathway promotes colorectal cancer metastasis[J]. EBio Medicine, 2017, 18:73-82.
[26]	Brown-Clay JD, Shenoy DN, Timofeeva O, et al. PBK/TOPK enhances aggressive phenotype in prostate cancer via beta-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion[J]. Oncotarget, 2015, 6(17):15594-15609. pmid: 25909225
[27]	Cote S, Simard C, Lemieux R. Regulation of growth-related genes by interleukin-6 in murine myeloma cells[J]. Cytokine, 2002, 20(3):113-120. pmid: 12453469
[28]	Uchida E, Suwa S, Yoshimoto R, et al. TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation[J]. Int J Oncol, 2019, 54(5):1785-1796. doi: 10.3892/ijo.2019.4740 pmid: 30864683
[29]	Hu F, Gartenhaus RB, Zhao XF, et al. c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas[J]. Leuk Res, 2013, 37(4):447-454. doi: 10.1016/j.leukres.2012.11.010 URL
[30]	Wang K, Wei J, Ma J, et al. Phosphorylation of PBK/TOPK Tyr74 by JAK2 promotes Burkitt lymphoma tumor growth[J]. Cancer Lett, 2022, 544:215812. doi: 10.1016/j.canlet.2022.215812 URL
[31]	Ota A, Hanamura I, Karnan S, et al. Novel interleukin-6 inducible gene PDZ-binding kinase promotes tumor growth of multiple myeloma cells[J]. J Interferon Cytokine Res, 2020, 40(8):389-405. doi: 10.1089/jir.2020.0111 URL
[32]	Park JH, Lin ML, Nishidate T, et al. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer[J]. Cancer Res, 2006, 66(18):9186-9195. doi: 10.1158/0008-5472.CAN-06-1601 URL
[33]	Dou X, Wei J, Sun A, et al. PBK/TOPK mediates geranylgeranylation signaling for breast cancer cell proliferation[J]. Cancer Cell Int, 2015, 15:27. doi: 10.1186/s12935-015-0178-0 pmid: 25745361
[34]	Li J, Weinberg MS, Zerbini L, et al. The oncogenic TBX3 is a downstream target and mediator of the TGF-beta1 signaling pathway[J]. Mol Biol Cell, 2013, 24(22):3569-3576. doi: 10.1091/mbc.e13-05-0273 URL
[35]	Lee YJ, Park JH, Oh SM. TOPK promotes epithelial-mesenchymal transition and invasion of breast cancer cells through upregulation of TBX3 in TGF-beta1/Smad signaling[J]. Biochem Biophys Res Commun, 2020, 522(1):270-277. doi: 10.1016/j.bbrc.2019.11.104 URL
[36]	Lee YJ, Park JH, Oh SM. Activation of NF-kappaB by TOPK upregulates Snail/Slug expression in TGF-beta1 signaling to induce epithelial-mesenchymal transition and invasion of breast cancer cells[J]. Biochem Biophys Res Commun, 2020, 530(1):122-129. doi: 10.1016/j.bbrc.2020.07.015 URL
[37]	Zykova TA, Zhu F, Lu C, et al. Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells[J]. Clin Cancer Res, 2006, 12(23):6884-6893. doi: 10.1158/1078-0432.CCR-06-0410 pmid: 17145805
[38]	Oh SM, Zhu F, Cho YY, et al. T-lymphokine-activated killer cell-originated protein kinase functions as a positive regulator of c-Jun-NH2-kinase 1 signaling and H-Ras-induced cell transformation[J]. Cancer Res, 2007, 67(11):5186-5194. doi: 10.1158/0008-5472.CAN-06-4506 URL
[39]	Kim DJ, Li Y, Reddy K, et al. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth[J]. Cancer Res, 2012, 72(12):3060-3068. doi: 10.1158/0008-5472.CAN-11-3851 pmid: 22523035
[40]	Joel M, Mughal AA, Grieg Z, et al. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo[J]. Mol Cancer, 2015, 14:121. doi: 10.1186/s12943-015-0398-x pmid: 26081429
[41]	Kar A, Zhang Y, Yacob BW, et al. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC[J]. Endocr Relat Cancer, 2019, 26(10):765-778. doi: 10.1530/ERC-19-0262 URL
[42]	Wang MY, Lin ZR, Cao Y, et al. PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: Driving tumor growth via ROS signaling and correlating with patient survival[J]. Oncotarget, 2016, 7(18):26604-26616. doi: 10.18632/oncotarget.v7i18 URL
[43]	Ishikawa C, Senba M, Mori N. Mitotic kinase PBK/TOPK as a therapeutic target for adult T?cell leukemia/lymphoma[J]. Int J Oncol, 2018, 53(2):801-814. doi: 10.3892/ijo.2018.4427 pmid: 29901068
[44]	Zhu K, Cheng X, Wang S, et al. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas[J]. Front Endocrinol (Lausanne), 2021, 12:706909. doi: 10.3389/fendo.2021.706909 URL
[45]	Park JH, Inoue H, Kato T, et al. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer[J]. Cancer Sci, 2017, 108(3):488-496. doi: 10.1111/cas.2017.108.issue-3 URL
[46]	Alachkar H, Mutonga M, Malnassy G, et al. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia[J]. Oncotarget, 2015, 6(32):33410-33425. doi: 10.18632/oncotarget.5418 pmid: 26450903
[47]	Ikeda Y, Park JH, Miyamoto T, et al. T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer[J]. Clin Cancer Res, 2016, 22(24):6110-6117. pmid: 27334838
[48]	Pirovano G, Roberts S, Brand C, et al. [(18)F]FE-OTS964: A small molecule targeting TOPK for in vivo pet imaging in a glioblastoma xenograft model[J]. Mol Imaging Biol, 2019, 21(4):705-712. doi: 10.1007/s11307-018-1288-6 pmid: 30357568
[49]	Gao G, Zhang T, Wang Q, et al. ADA-07 Suppresses solar ultraviolet-induced skin carcinogenesis by directly inhibiting TOPK[J]. Mol Cancer Ther, 2017, 16(9):1843-1854. doi: 10.1158/1535-7163.MCT-17-0212 pmid: 28655782
[50]	Gao T, Hu Q, Hu X, et al. Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis[J]. Cancer Lett, 2019, 445:11-23. doi: S0304-3835(18)30737-7 pmid: 30590102
[51]	Zheng M, Luan S, Gao S, et al. Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase[J]. Oncotarget, 2017, 8(24):39143-39153. doi: 10.18632/oncotarget.16609 pmid: 28388576
[52]	Zeng X, Liu L, Zheng M, et al. Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase[J]. Oncotarget, 2016, 7(16):22460-22473. doi: 10.18632/oncotarget.7984 pmid: 26967058
[53]	Hu QF, Gao TT, Shi Y J, et al. Design, synthesis and biological evaluation of novel 1-phenyl phenanthridin-6(5H)-one derivatives as anti-tumor agents targeting TOPK[J]. Eur J Med Chem, 2019, 162:407-422. doi: 10.1016/j.ejmech.2018.11.007 URL

肿瘤类型	信号通路	在肿瘤中所发挥的作用
肺癌^[17-18]	p38MAPK	促进肿瘤增殖
	PI3/PTEN/AKT信号通路	促进肿瘤转移
食管鳞状细胞癌^[20]	Src/GSK3β/STAT3信号通路	促进肿瘤转移
	ERK通路	促进肿瘤转移
胃癌^[21]	TP53突变依赖方式通过p53失活	促进肿瘤转移
	TP53突变依赖方式通过TPEN下调	促进肿瘤增殖
肝细胞性肝癌^[22]	FOXM1/PBK/β-catenin信号通路	促进肿瘤的发生
结直肠癌^[23⇓-25]	MAPK-ERK通路	促进肿瘤的发生
	SRC阻断泛素化降解途径	促进肿瘤的发生
	PBK在Ser250位点磷酸化PRPK	促进肿瘤的转移
前列腺癌^[26]	β-catenin-TCF/LEF信号通路	促进肿瘤转移
淋巴瘤^[29-30]	c-Myc-E2F1-PBK信号轴	参与肿瘤的生长
	JAK2/TOPK/H3信号通路	促进肿瘤增殖
骨髓瘤	IL-6/JAK/Stat3信号通路	促进肿瘤增殖和抑制肿瘤凋亡
乳腺癌^{[32⇓⇓⇓-36]}	在Ser10位点磷酸化H3	促进细胞增殖
	香叶基糖基化信号通路	促进肿瘤细胞增殖
	Hippo-YAP/TAZ信号通路	促进肿瘤细胞增殖
	TGF-β1/Smad信号通路	促进上皮间质转化和肿瘤侵袭
	NF-kB/Snail信号通路	促进上皮间质转化和肿瘤侵袭
黑色素瘤^[4,37]	磷酸化H2AX	抑制肿瘤细胞凋亡
	在Ser32c处磷酸化Prx1	抑制肿瘤细胞凋亡
皮肤癌^[38]	磷酸化JNK	参与肿瘤的发生

肿瘤类型	信号通路	在肿瘤中所发挥的作用
肺癌^[17-18]	p38MAPK	促进肿瘤增殖
	PI3/PTEN/AKT信号通路	促进肿瘤转移
食管鳞状细胞癌^[20]	Src/GSK3β/STAT3信号通路	促进肿瘤转移
	ERK通路	促进肿瘤转移
胃癌^[21]	TP53突变依赖方式通过p53失活	促进肿瘤转移
	TP53突变依赖方式通过TPEN下调	促进肿瘤增殖
肝细胞性肝癌^[22]	FOXM1/PBK/β-catenin信号通路	促进肿瘤的发生
结直肠癌^[23⇓-25]	MAPK-ERK通路	促进肿瘤的发生
	SRC阻断泛素化降解途径	促进肿瘤的发生
	PBK在Ser250位点磷酸化PRPK	促进肿瘤的转移
前列腺癌^[26]	β-catenin-TCF/LEF信号通路	促进肿瘤转移
淋巴瘤^[29-30]	c-Myc-E2F1-PBK信号轴	参与肿瘤的生长
	JAK2/TOPK/H3信号通路	促进肿瘤增殖
骨髓瘤	IL-6/JAK/Stat3信号通路	促进肿瘤增殖和抑制肿瘤凋亡
乳腺癌^{[32⇓⇓⇓-36]}	在Ser10位点磷酸化H3	促进细胞增殖
	香叶基糖基化信号通路	促进肿瘤细胞增殖
	Hippo-YAP/TAZ信号通路	促进肿瘤细胞增殖
	TGF-β1/Smad信号通路	促进上皮间质转化和肿瘤侵袭
	NF-kB/Snail信号通路	促进上皮间质转化和肿瘤侵袭
黑色素瘤^[4,37]	磷酸化H2AX	抑制肿瘤细胞凋亡
	在Ser32c处磷酸化Prx1	抑制肿瘤细胞凋亡
皮肤癌^[38]	磷酸化JNK	参与肿瘤的发生

名称	肿瘤类型	发挥作用
HI-TOPK-032	结肠癌^[39]	抑制肿瘤生长
	成人T细胞白血病/淋巴瘤^[40]	抑制肿瘤生长
	神经胶质瘤^[41]	抑制肿瘤生长
	肾上腺皮质腺癌^[42]	阻断肿瘤细胞增殖
	鼻咽癌^[43]	导致肿瘤体积缩小
	泌乳素瘤^[44]	抑制泌乳素瘤生长和泌乳素分泌
OTS514	急性髓系白血病^[45]	抑制肿瘤生长
	肺癌^[46]	抑制肿瘤生长
	卵巢癌^[47]	抑制肿瘤生长
OTS964	肺癌^[46]	抑制肿瘤生长
ADA-07	皮肤癌^[49]	缩小肿瘤体积
SKLB-C05	结直肠癌^[50]	抑制肿瘤生长和转移
泮托拉唑/艾普拉唑	结直肠癌^[51-52]	抑制肿瘤生长
1-苯基菲啶-6(5H )酮衍生物	结直肠癌^[53]	抑制肿瘤生长

名称	肿瘤类型	发挥作用
HI-TOPK-032	结肠癌^[39]	抑制肿瘤生长
	成人T细胞白血病/淋巴瘤^[40]	抑制肿瘤生长
	神经胶质瘤^[41]	抑制肿瘤生长
	肾上腺皮质腺癌^[42]	阻断肿瘤细胞增殖
	鼻咽癌^[43]	导致肿瘤体积缩小
	泌乳素瘤^[44]	抑制泌乳素瘤生长和泌乳素分泌
OTS514	急性髓系白血病^[45]	抑制肿瘤生长
	肺癌^[46]	抑制肿瘤生长
	卵巢癌^[47]	抑制肿瘤生长
OTS964	肺癌^[46]	抑制肿瘤生长
ADA-07	皮肤癌^[49]	缩小肿瘤体积
SKLB-C05	结直肠癌^[50]	抑制肿瘤生长和转移
泮托拉唑/艾普拉唑	结直肠癌^[51-52]	抑制肿瘤生长
1-苯基菲啶-6(5H )酮衍生物	结直肠癌^[53]	抑制肿瘤生长

PDZ结合激酶/T淋巴细胞因子激活的杀伤细胞源性蛋白激酶的作用机制及其在肿瘤治疗中的潜在价值

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 53

相关文章 13

编辑推荐

Metrics

本文评价

[1]	李百远, 李元军. 他汀类药物辅助抗结核作用机制及临床价值[J]. 临床荟萃, 2022, 37(2): 166-169.
[2]	简郭进, 张斌. 沙库巴曲缬沙坦在心血管疾病中的研究进展[J]. 临床荟萃, 2021, 36(11): 1041-1045.
[3]	宫嫚;罗生强;张宁;孙永强;景婧;刘红虹;张帆;吴欣;杜宁;李筠. 酒精性肝病的发病机制研究进展[J]. 临床荟萃, 2013, 28(3): 350-352.
[4]	罗绍友;陈红;房芳;肖颖;王海波;张卫国;王林;王原. 厄洛替尼治疗吉非替尼耐药老年非小细胞肺癌脑转移的疗效[J]. 临床荟萃, 2012, 27(4): 301-303.
[5]	曹红花;程昊钰. 粒细胞集落刺激因子在急性髓系白血病治疗中的应用进展[J]. 临床荟萃, 2011, 26(7): 637-641.
[6]	李通;田红英;毛志锋. Rho/Rho激酶与缺血性脑组织损害[J]. 临床荟萃, 2011, 26(3): 262-267.
[7]	张月馨;常靓;刘巍. 抗癌药雷替曲塞的研究进展[J]. 临床荟萃, 2011, 26(21): 1928-1931.
[8]	李杨;赖雁. 螺旋藻多糖抗肿瘤作用的研究进展[J]. 临床荟萃, 2011, 26(2): 170-172.
[9]	崔荣;毋永娟;杨燕霞;华云旗;刘丽萍;谭亚琴;张文慧;袁海清. 吉非替尼与多西他赛单药治疗老年晚期肺腺癌的疗效及对心肌损伤的初步分析[J]. 临床荟萃, 2011, 26(13): 1131-1133.
[10]	陈素芹;李君;夏金英. 核转录因子κB在炎性相关癌症中的作用[J]. 临床荟萃, 2010, 25(16): 1471-0.
[11]	张玉静;杨星林;任长杰. 丹参酮Ⅱ A对心血管影响研究的进展[J]. 临床荟萃, 2009, 24(18): 1653-1654.
[12]	韩依轩;崔刘福. 白细胞介素17与类风湿关节炎关系的研究进展[J]. 临床荟萃, 2008, 23(23): 1747-0.
[13]	刘阳. 唑吡旦的不良反应[J]. 临床荟萃, 2008, 23(22): 1670-1672.